Risperdal has been approved to treat schizophrenia, acute manic or mixed episodes associated with bipolar I disorder, and irritability associated with autism in children and adolescents.  A consolidated class action complaint has been filed against Risperdal manufacturers Janssen, L.P. and Johnson & Johnson alleging the companies illegally market and promote Risperdal for "off-label" uses - that is, for uses not approved by the FDA. 

Risperdal off-label uses for adults include: 1) dementia, 2) Alzheimer's disease, 3) depression for patients who do not benefit from selective serotonin reuptake inhibitors ("SSRI"), 4) Obsessive-Compulsive Disorder ("OCD") for patients who do not respond adequately to SSRI therapy, 5) Post-Traumatic Stress Disorder, 6) Personality Disorders, 7) anxiety, 8) sleep disorders, 9) anger management, 10) mood enhancement or mood stabilization and 11) behavioral disorders not caused by adult schizophrenia or bipolar I disorder.  Risperdal has also been prescribed off-label for children and adolescents to treat: 1) general mood and behavior disorders, 2) Attention Deficit Disorder, 3) Attention Deficit Hyperactivity Disorder, 4) Tourette's Syndrome, and 5) the general treatment of autism.  The complaint alleges that although less expensive alternatives to Risperdal were available on the market, the defendants' scheme forced consumers to pay higher co-payments and out-of-pocket costs for Risperdal.